Prof. Dr. Andy Goren has over 20 years of experience in research, development and commercialization of breakthrough therapeutics and diagnostics.
Among the list of many firsts in dermatology, Prof. Goren was the first to develop a clinical genetic test for predicting androgenetic alopecia, the first to discover epigenetic markers predicting anti-androgen therapy response in female androgenetic alopecia, the first to develop a clinical acne vulgaris antibiotic response test based on P. Acnes bacterial genomics, and the first to develop a rapid test for predicting minoxidil response in androgenetic alopecia.
Prof. Goren is actively involved in the development, commercialization, and listing of several drugs and medical devices including new therapies for female pattern hair loss, chemotherapy induced alopecia, excessive hair shedding, and female sexual dysfunction. His latest research involves the development of dermatology therapies based on genetically modified organisms.…
We use cookies to ensure that we give you the best experience on our website. You can change your cookie settings at any time. Find out more about cookies here.
